Senolytics ameliorate cognitive decline in D-galactose-induced aging mice by inhibiting astrocytic cholesterol accumulation.
Key claim: Dasatinib plus quercetin senolytics reverse cognitive decline in D-galactose-induced aging mice by downregulating cholesterol biosynthesis in astrocytes, reducing lipid accumulation and neuroinflammation.
Abstract
Cellular senescence plays a crucial role in brain aging and the decline of cognitive abilities. Although senolytic treatments, particularly the combination of dasatinib and quercetin (D+Q), show potential for improving cognition, the specific mechanisms involved are not well understood. In this study, we present strong evidence that senolytics enhance cognitive function by modulating cholesterol biosynthesis in astrocytes. Using a murine model of accelerated aging (via D-galactose exposure), we show that administering D + Q results in significant improvements in cognitive performance and a decrease in cellular senescence. A comprehensive multi-omics analysis subsequently demonstrated that senolytics are especially effective at downregulating cholesterol biosynthesis in the hippocampus. Notably, this effect was localized to astrocytes, where senolytics significantly reduced intracellular lipid accumulation and subsequent neuroinflammation. Critically, pharmacological activation of cholesterol synthesis and genetic overexpression of Hsd17b7, a key enzyme in the cholesterol synthesis pathway, in astrocytes reversed the anti-senescence benefits of senolytics in vitro, establishing a causal link between cholesterol pathway inhibition and the therapeutic effects. Overall, our work identifies the suppression of astrocytic cholesterol biosynthesis as a fundamental mechanism of senolytic action, repositioning these compounds as modulators of brain lipid metabolism and highlighting a promising therapeutic axis for combating age-related cognitive decline.
Why this matters
This finding extends the canonical D+Q senolytic pharmacology into a specific CNS metabolic mechanism — astrocytic cholesterol biosynthesis — and links it causally to cognitive decline in a D-galactose aging model via multi-omics and pharmacologic/genetic reversal. It pulls astrocyte lipid metabolism into the senescence-neuroinflammation axis, adjacent to prior HMGCR-cholesterol-senescence signals in synovium, and offers a mechanistic handle distinct from broad SASP dampening. It remains a single preclinical model with no human translation, and D-gal is a chemically induced aging surrogate rather than natural aging.